Cargando…

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy

BACKGROUND: the interest of clinical reaseach in polymorphisms and epigenetics in migraine has been growing over the years. Due to the new era of preventative migraine treatment opened by monoclonal antibodies (mAbs) targeting the signaling of the calcitonin-gene related peptide (CGRP), the present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scuteri, Damiana, Corasaniti, Maria Tiziana, Tonin, Paolo, Nicotera, Pierluigi, Bagetta, Giacinto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325208/ https://www.ncbi.nlm.nih.gov/pubmed/34330208 http://dx.doi.org/10.1186/s10194-021-01295-7

Ejemplares similares

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
por: Scuteri, Damiana, et al.
Publicado: (2022)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Corasaniti, Maria Tiziana, et al.
Publicado: (2023)

Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
por: Siersbæk, Nikolaj, et al.
Publicado: (2023)

Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience
por: Silvestro, Marcello, et al.
Publicado: (2021)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Dementia and COVID-19: A Case Report and Literature Review on Pain Management
por: Scuteri, Damiana, et al.
Publicado: (2022)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a randomized, double‐blind, placebo‐controlled trial to assess the efficacy of furocoumarin‐free bergamot loaded in a nanotechnology‐based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia
por: Scuteri, Damiana, et al.
Publicado: (2021)

Migraine therapeutics differentially modulate the CGRP pathway
por: Bhakta, Minoti, et al.
Publicado: (2021)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

CGRP as a Migraine Inducing Substance
por: Olesen, J., et al.
Publicado: (2001)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

Effect of Xiongmatang Extract on Behavioral and TRPV1-CGRP/CGRP-R Pathway in Rats With Migraine
por: Liu, Dingding, et al.
Publicado: (2022)

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
por: Straube, Andreas, et al.
Publicado: (2023)

Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis
por: Scuteri, Damiana, et al.
Publicado: (2023)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Future targets for migraine treatment beyond CGRP
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol
por: Scuteri, Damiana, et al.
Publicado: (2022)

ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain Development
por: Pignolo, Loris, et al.
Publicado: (2022)

Editorial: “Novel Pain Therapeutics: From Basic Research to Clinical Translation and Rehabilitation”
por: Scuteri, Damiana, et al.
Publicado: (2021)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

New Anti-CGRP Medications in the Treatment of Vestibular Migraine
por: Hoskin, Justin L., et al.
Publicado: (2022)

The Responses to CGRP in the Territory of the Posterior Cerebral Artery in Migraine
por: Visočnik, Darja, et al.
Publicado: (2022)

Shared and independent roles of CGRP and PACAP in migraine pathophysiology
por: Kuburas, Adisa, et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway
por: Zhou, Zifan, et al.
Publicado: (2023)

Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia
por: Scuteri, Damiana, et al.
Publicado: (2022)

Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis
por: Scuteri, Damiana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mjlsa33taja2mmpmvimgbkaurs